Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1994-05-17
2000-04-04
Tsang, Cecilia
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514579, 514588, 536 2714, 536 282, 536 278, 560313, A61K 3170
Patent
active
060461756
ABSTRACT:
A method for inhibiting replication of reverse transcriptase dependent virus in plant or animal cells, comprising the step of administering to said cells a compound that depletes the intracellular pool of deoxyribonucleoside phosphate in an amount effective to inhibit replication of said virus. Hydroxyurea is one such suitable compound. Also disclosed is a method for producing incomplete reverse-transcriptase dependent viral DNA, by administering a deoxyribonucleoside phosphate-depleting drug to cells infected with such a virus.
REFERENCES:
patent: 4708818 (1987-11-01), Montagnier et al.
patent: 5026687 (1991-06-01), Yarchoan et al.
patent: 5110600 (1992-05-01), Green
patent: 5300059 (1994-04-01), Rubinstein et al.
patent: 5521161 (1996-05-01), Malley, I et al.
patent: 5736526 (1998-04-01), Malley, II et al.
patent: 5736527 (1998-04-01), Malley, III et al
Villani et al., "Pharmacokinetics of Hydroxyurea in Patients Infected with Human Immunodeficiency Virus Type I," Journal of Clinical Pharmacology, 36, 117-121 (1996).
Gao et al., "Low Levels of Deoxynucleotides in Peripheral Blood Lymphocytes: A Strategy to Inhibit Human Immunodeficiency Virus Type 1 Replication," Proc. Nat. Acad. Sci. USA, 90, 8925-8928 (Oct. 1993).
Biochemicals/Organic Compounds for Research and Diagnostic Reagents, Sigma Chemical Co. (catalog), St. Louis, MO, 1992, pp. 321, 341-342.
Feorino et al., "Prevention of Activation of HIV-1 by Antiviral Agents in OM-10.1 Cells," Antiviral Chemistry & Chemotherapy, 4(1), 55-63 (1993).
Snyder et al. (I), "Effects of Hydroxyurea and Thymidine Derivatives on the Uptake and Metabolism of Deoxycytidine and Arabinosylcytosine in Log Phase and Contact-Inhibited Human Fibroblasts," Molecular Pharmacology, 28(6), 574-580 (1985); see p. 578 in particular.
Licastro et al., "Inhibition of Polymerases-.alpha. and -.beta. Completely Blocks DNA Repair Induced by UV Irradiation in Cultured Mouse Neuronal Cells," Biochem. Biophys. Res. Comm., 132(3), 929-933 (Nov. 15, 1985).
Busso et al., "Cellular Pharmacology and Anti-HIV Activity of 2',3'-Dideoxyguanosine," AIDS Res. Human Retroviruses, 6(9), 1139-1146 (1990).
R. S. Root-Bernstein(I), "AIDS Is More Than HIV: Part I," Genetic Engineering News, Sep. 1, 1992, pp. 4-6.
R. S. Root-Bernstein(II), "AIDS Is More Than HIV: Part II," Genetic Engineering News, Sep. 15, 1992, pp. 4-5.
"Kaposi's Sarcoma and Pneumocystis Pneumonia Among Homosexual Men," Morbidity Mortality Weekly Rept., vol. 30(25), Centers for Disease Control, Jul. 3, 1981, pp. 305-308.
Barre-Sinoussi et al., "Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)," Science, 220, 868-871 (1983).
Fauci (I), "The Human Immunodeficiency Virus: Infectivity and Mechanisms of Pathogenesis," Science, 239, 617-622 (Feb. 1988).
Fauci (II), "Multifactoral Nature of Human Immunodeficiency Virus Disease: Implications for Therapy," Science, 262, 1011-1018 (Nov. 12, 1993).
Zack et al., "HIV-1 Entry into Quiescent Primary Lymphocytes: Molecular Analysis Reveals a Labile, Latent Viral Structure," Cell, 61, 213-222 (Apr. 20, 1990).
Bukrinsky et al., "Quiescent T Lymphocytes as an Inducible Virus Reservoir in HIV-1 Infection," Science, 254, 233-237 (Oct. 18, 1991).
Schnittman et al., "The Reservoir for HIV-1 in Human Peripheral Blood Is a T Cell that Maintains Expression of CD4," Science, 245, 305-308 (Jul., 1989).
Fox et al., "Lymphoid Germinal Centers Are Resevoirs of Human Immunodeficiency Virus Type 1 RNA," J. Infectious Diseases, 164, 1051-1057 (Dec., 1991).
Hirsch et al., "Therapy for Human Immunodeficiency Virus Infection," N. Engl. J. Medicine, 328(23), 1686-1695 (Jun. 10, 1993).
Pauwels et al., "Rapid and Automated Tetrazolium-Based Colorimetric Assay for the Detection of Anti-HIV Compounds," J. Virological Methods, 20, 309-321 (1988).
Yarchoan et al., "Clinical Pharmacology of 3'-Azido-2', 3'-dideoxythymidine (Zidovudine) and Related Dideoxynucleosides," N. Engl. J. Medicine, 321(11), 726-738 (Sep. 14, 1989).
Chow et al., "Use of Evolutionary Limitations of HIV-1 Multidrug Resistance to Optimize Therapy," Nature, 361, 650-654 (1993).
Lori et al., "Hydroxyureas an Inhibitor of Human Immunodeficiency Virus-Type 1 Replication," Science, 266, 801-805 (Nov. 4, 1994).
Karlsson et al., "Hydroxyurea Increases the Phosphorylation of 3'-fluorothymidine and 3'-Azidothymidine in CEM Cells," Eur. J. Biochem., 186, 689-694 (1989).
Marquez et al., "Acid-Stable 2'-Fluoro Purine Dideoxynucleosides as Active Agents Against HIV," J. Med. Chem., 33(3), 978-985 (1990).
Snyder et al. (II), "The Accumulation of DNA Breaks Due to Incision; Comparative Studies with Various Inhibitors," Ch. 2 in DNA Repair and Its Inhibition, Nucleic Acids Symposium Series No. 13, Collins et al. eds., IRL Press, Oxford, England, 1984, pp. 13-33.
Vila et al., "Absence of Viral Rebound After Treatment of HIV-Infected Patients with Didanosine [ddI] and Hydroxycarbamide [aka Hydroxyurea]," Lancet, 350(9078), 635-636 (Aug. 30, 1997).
Schoofs, "The Berlin Patient," The New York Times Magazine, pp. 32-35, Jun. 21, 1998.
Altman, L.K., New York Times, p. 38, Sunday, Sep. 17, 1995, "Study Challenges AZT Role as the Chief Drug for H.I.V.".
Biron et al., Journal of Acquired Immune Deficiency Syntromes and Human Retrovirology, 10(1):36-40, 1995, "Anti-HIV Activity of the Combination of Didanosine and Hydroxyurea in HIV-1-Infected Indivuduals".
Fischl, AIDS Clin. Rev., 94:167-187, 1993, "Treatment of HIV Disease in 1993/1994".
Gao, Aids Research and Human Viruses, 10(1): Supp. 3, Abstract No. 355, 1994, (Sep. 1994). "Mechanisms of the Enhanced Anti-HIV-1 Activites of 2', 3'-Dideoxynucleoside Analogs by Hydroxyurea".
Gao et al., Mol. Pharmacol., 46(4): 767-772, 1994, (Oct. 1994). "Anti-Human Immunodeficiency Virus Type 1 Activity of Hydroxyurea in Combination with 2', 3'-Dideoxynucleosides".
Goulaiouic et al., C.R. Acad. Sci. Paris, 317: 430-436, 1994. "Potentiation of 2', 3'-Dideoxycytidine (ddc) by Hydroxyurea and Thymidine on the Moloney Murine Leukemia Virus (MoMLV) Early Replicative Steps".
Goulaouic et al., Virology, 200: 87-97, 1994. "Exogenous Nucleosides Promote the Completionof MoMLV DNA Synthesis on GO-Arrested Balb c/3t3 Fibroblasts".
Hao et al., Molecular Pharmacolocy, 34:431-435, 1988, "Factors Determining the Activity of 2', 3'-Dideoxynucleosides in Supressing Human Immunodeficiency Virus In Vitro".
Langreth, The Wall Street Journal, p. B12, Nov. 21, 1995, "FDA Gives Approval to Glaxo, Sequus to Market Separate AIDS Therapies".
Lien, Progress in Drug Research, 31: 101-126, 1987, "Ribonucleotide reductase inhibitors as anticancer and antiviral agents".
Lori et al., International Conference on Aids, 10(1): 8, Abstract No. 007b, 1994 (Aug. 7-12, 1994). "Hydroxyurea as a Novel Potent Inhibitor of HI-1 Replication".
Malley et al., The Lancet, 343(8908): 1292, 1994, (May 21, 1994). "Suppression of HIV Production in Resting Lymphocytes by Combining Didanosine and Hydroxamate Compounds".
Malley, Proc. Nat. Acad. Sci. USA, 91(23): 11017-11021, Nov. 1994, "Synergistic Anti-Human Immunodeficiency Virus Type 1 Effect of Hydroxamate Compounds with 2', 3'-Dideoxyinosine in Infected Resting Human Lymphocytes".
Meyerhans et al., Journal of Virology, 68(1): 535-540, 1994, (Jan. 1994). "Restriction and Enhancement of Human Immunodeficiency Virus Type 1 Replication by Modulation of Intracellular Deoxynucleosides Triphosphate Pools".
New York Times, p. B19, Nov. 24, 1995, "Study Puts Risk of H.I.V. in Young U.S. Men at 1 in 92".
Vila et al., Lancet, 348(9021): 203-204, Jul. 20, 1996, "1-year follow-up of the use of hydroxycarbamide and didanosine in HIV Infection".
Medina, D.J. et al., "Ganciclovir Antagonizes the Anti-Human Immunodeficiency Virus Type I Activity of Zidovudine and Didanosine In Vitro", Antimicrobial Agents and Chemotherapy, vol. 36, No. 5, pp. 1127-1130, May 1992.
Simonelli, C. et al.; "Hydroxyurea as an Antiviral Drug in HIV Infected Patients: Clinical, Immunological and Virological Evaluation", Presented at: The Fifth European Conference on Clinical Aspects and Treateme
Cara Andrea
Gallo Robert C.
Gao Wen-Yi
Lori Franco
Crane L. Eric
The United States of America as represented by the Department of
Tsang Cecilia
LandOfFree
Procedure to block the replication of reverse transcriptase depe does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Procedure to block the replication of reverse transcriptase depe, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Procedure to block the replication of reverse transcriptase depe will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-365139